- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Calidi Biotherapeutics GAAP EPS of -$0.18 misses by $0.03 | 2 | Seeking Alpha | ||
| 14.05. | Calidi Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights | 76 | GlobeNewswire (Europe) | Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered... ► Artikel lesen | |
| 02.05. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.04. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 | 130 | GlobeNewswire (Europe) | SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor... ► Artikel lesen | |
| 23.04. | Calidi Biotherapeutics names Poma as CEO | 4 | Seeking Alpha | ||
| 23.04. | Calidi Biotherapeutics appoints new CEO | 2 | Investing.com | ||
| 23.04. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.04. | US FDA clears Calidi's CLD-201 for clinical development in solid tumours | 1 | Pharmaceutical Business Review | ||
| 10.04. | Calidi Biotherapeutics Names Guy Travis Clifton Chief Medical Officer | 1 | RTTNews | ||
| 10.04. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 31.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 31.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights | 72 | GlobeNewswire (Europe) | Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial... ► Artikel lesen | |
| 28.03. | Calidi Biotherapeutics sinks after pricing $3.9M registered direct offering | 4 | Seeking Alpha | ||
| 28.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement | 1 | GlobeNewswire (USA) | ||
| 14.03. | RedChip Companies, Inc.: Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 297 | ACCESS Newswire | ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip... ► Artikel lesen | |
| 10.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 24,010 | -1,62 % | Moderna: Regierungs-Ärger bei Vogelgrippe-Impfstoff | Moderna hat Zwischenergebnisse aus einer Phase-1/2-Studie zu seinem Pandemie-Impfstoff mRNA-1018 gegen die H5-Vogelgrippe vorgestellt. Demnach erzielte der mRNA-Kandidat des US-Konkurrenten von BioNTech... ► Artikel lesen | |
| OCUGEN | 0,779 | +0,85 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
| ABCELLERA BIOLOGICS | 2,186 | +2,87 % | Why AbCellera Biologics Stock Raced Nearly 6% Higher Today | ||
| ALIGOS THERAPEUTICS | 5,600 | +1,82 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 3,620 | +1,12 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| BIONTECH | 99,25 | +1,79 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,366 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.